Novel coumarin ruthenium complexes, their synthesis methods and applications
The synthesis of novel coumarin-ruthenium complexes has solved the problems of toxicity and drug resistance of existing antitumor drugs, achieving effective inhibition of drug-resistant human lung cancer cells and low toxicity to normal cells, and has potential medicinal value.
Patent Information
- Application Number
- CN202410566164.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-09
- Publication Date
- 2026-11-17
AI Technical Summary
Existing anti-tumor drugs such as cisplatin have shown toxic side effects and drug resistance problems with long-term use, and coumarin ruthenium complexes have limited effects on human lung cancer cisplatin-resistant cell line A549/DDP cells.
Novel coumarin-ruthenium complexes were synthesized. Three novel coumarin-ruthenium complexes, YNU-4i, YNU-4j, and YNU-4k, were prepared by reacting coumarin derivatives with the metal salt cis-Ru(DMSO)4Cl2. After purification, they were used to conduct anticancer activity and toxicity experiments on human lung cancer drug-resistant cell line A549/DDP and normal HEK293 cells.
The novel coumarin-ruthenium complex exhibited good inhibitory effects on the drug-resistant human lung cancer cell line A549/DDP, with low toxicity to normal cells, overcoming cisplatin resistance and possessing potential medicinal value.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to novel coumarin ruthenium complexes, their synthesis methods, and applications. Background Technology
[0002] A key characteristic of tumor cell development is the unchecked proliferative capacity of tumor cells, which are not regulated by the normal body. Therefore, inhibiting tumor cell growth or promoting tumor cell apoptosis is an important means of preventing tumor progression. The search for novel, highly effective, low-toxicity anti-tumor drugs that can directly target specific tumors has always been a persistent goal of humankind.
[0003] Cisplatin has the function of inhibiting tumor cell growth, and clinically, it has shown good therapeutic effects on solid tumors such as ovarian cancer, lung cancer, and bladder cancer. However, during long-term use, cisplatin's numerous toxic side effects, such as nephrotoxicity, ototoxicity, and neurotoxicity, gradually emerged. Simultaneously, some tumor cells developed resistance to cisplatin. Based on cisplatin, platinum-based drugs such as carboplatin and oxaliplatin were further developed. These drugs reduced the toxic side effects to some extent, but cross-resistance issues still exist, and they are ineffective against some tumor cells. Therefore, the development of non-platinum-based antitumor drugs is of great significance.
[0004] Coumarins are a class of natural compounds with a benzo-α-pyran structure, widely studied for their small molecular weight, simple synthesis, and high bioavailability. Numerous studies have shown that coumarins and their derivatives possess anti-inflammatory, antioxidant, antiviral, and antitumor effects. In recent years, metal-based antitumor drugs have gained increasing favor among researchers, who have begun to incorporate coumarin groups into metal drugs to enhance their antitumor activity.
[0005] In the existing technology, a series of coumarin platinum, palladium and other metal anticancer complexes have been reported, which have good anticancer effects on various tumor cells (Qin, Q.-P.; et al. European Journal of Medicinal Chemistry, 2019, 184, 111751.). Ruthenium complexes of coumarin derivatives have been reported in existing technologies. For example, Li Yanci et al. synthesized 11 coumarin β-diketone derivatives using salicylaldehyde and its derivatives as raw materials. Through coordination with [RuCl2(cym)]2, they obtained 11 class I arylruthenium(II) complexes. Further, by substituting Cl with perfluorooctylethyl imidazole, they obtained 11 class II arylruthenium(II) complexes. Cellular activity studies using the MTT assay revealed that class II arylruthenium(II) complexes exhibited good cytotoxicity against human cervical cancer cells, human breast cancer cells, human lung cancer cells, and human gastric cancer cells, while class I arylruthenium(II) complexes showed almost no cytotoxicity. Studies also showed that complexes with perfluorooctylethyl imidazole as the ligand exhibited significantly better cytotoxicity than the corresponding non-fluorinated alkyl imidazole complexes. Therefore, ruthenium complexes with different active ligands can exhibit different and unpredictable cytotoxicities against different tumor cells.
[0006] In addition, Liang Hong et al. reported that the coumarin ruthenium anticancer complex has a high inhibitory effect on NCI-H460 cancer cells (Liang, H.; et al. ACS Med. Chem. Lett. 2019, 10, 936-940), IC50. 50 The value was as low as 0.30±0.02µM. However, the anticancer effect of coumarin ruthenium complex on human lung cancer cisplatin-resistant cell line A549 / DDP remains a blank.
[0007] There are currently no reports on the antitumor effects of ruthenium complexes with coumarin derivatives as active ligands; the structural formulas of the aforementioned coumarin derivatives are as follows:
[0008] .
[0009] The information disclosed in this background section is intended only to enhance the understanding of the overall background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art known to those skilled in the art. Summary of the Invention
[0010] The purpose of this invention is to provide novel coumarin ruthenium complexes, their synthesis methods, and applications. The novel coumarin ruthenium complexes provided have excellent antitumor activity and potential application value, and are expected to be used to prepare antitumor drugs.
[0011] To achieve the above objectives, the present invention provides the following technical solution:
[0012] A novel coumarin ruthenium complex, the structural formula of which is as follows:
[0013] ,
[0014] Where R3 is H or Cl; R4 is Cl or Br.
[0015] More specifically, the synthesis method of the novel coumarin-ruthenium complex is as follows: 0.2 mmol of coumarin derivative and 0.2 mmol of metal salt cis-Ru(DMSO)4Cl2 are weighed, followed by the addition of 2.0 mL CH3OH and 0.5 mL CH2Cl2. After reacting at 50-90℃ for 3 days, the mixture is cooled to room temperature, filtered, and the crude product is obtained. Then, using CH2Cl2 / MeOH with a volume ratio of 100:1-20:1 as the eluent, the product is purified by Al2O3 column chromatography to obtain a reddish-brown product, which is the novel coumarin-ruthenium complex.
[0016] More specifically, the structural formula of the coumarin derivative is as follows:
[0017]
[0018] Where R3 is H or Cl; R4 is Cl or Br.
[0019] More specifically, the method for synthesizing the coumarin derivative is as follows: Weigh 0.05 mol of 2-pyridineacetonitrile and 0.05 mol of 4,5-dichlorosalicylic acid, 5-bromosalicylic acid, or 5-chlorosalicylic acid, then add 40.0 mL of anhydrous ethanol and 1.5 mL of piperidine, stir at 37°C for 8.0 h, then react at 65°C for 8.0 h, and filter to obtain the iminocoumarin derivative; then add 35.0 mL of 15% HCl and 5.0 mL of H2O to the iminocoumarin derivative, react at 95°C for 9.0 h, neutralize with concentrated ammonia water to neutral, filter to obtain a light yellow solid; then, under heating conditions, dissolve and recrystallize the obtained yellow solid with 10.0 mL of methanol, repeat 3 times, filter, and finally obtain a pure light yellow product, which is the coumarin derivative.
[0020] The second objective of this invention is to provide the application of novel coumarin ruthenium complexes in the preparation of antitumor drugs.
[0021] More specifically, the tumor in question is human lung cancer.
[0022] The third objective of this invention is to provide an in vitro and in vivo antitumor drug, wherein the novel coumarin ruthenium complex is the active ingredient.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] This invention synthesizes three novel coumarin-ruthenium complexes by reacting coumarin derivatives with the metal salt cis-Ru(DMSO)4Cl2. Anticancer activity and toxicity experiments on the drug-resistant human lung cancer cell line A549 / DDP and normal HEK293 cells revealed that the novel coumarin-ruthenium complexes of this invention exhibit excellent inhibitory effects on the drug-resistant human lung cancer cell line A549 / DDP and minimal toxicity to normal HEK293 cells. This indicates that the novel coumarin-ruthenium complexes of this invention demonstrate superior antitumor activity and good selectivity, while also overcoming cisplatin resistance, possessing potential pharmaceutical value and promising applications in the preparation of various antitumor drugs. Attached Figure Description
[0025] Figure 1 The 1H NMR spectrum of coumarin-derived H-QL3a;
[0026] Figure 2 The carbon NMR spectrum of coumarin-derived H-QL3a;
[0027] Figure 3 The 1H NMR spectrum of coumarin-derived H-QL3b;
[0028] Figure 4 The 1H NMR spectrum of coumarin-derived H-QL3c;
[0029] Figure 5 The 1H NMR spectrum of the novel coumarin ruthenium complex YNU-4i;
[0030] Figure 6 The 1H NMR spectrum of the novel coumarin ruthenium complex YNU-4j;
[0031] Figure 7 The 1H NMR spectrum of the novel coumarin ruthenium complex YNU-4k. Detailed Implementation
[0032] The technical solution of this invention patent will be clearly and completely described below. Obviously, the described embodiments are some embodiments of this invention, but not all embodiments.
[0033] 1. Materials and Methods
[0034] 1.1 Synthesis of Coumarin Derivatives
[0035] In a 250 mL round-bottom flask, 0.05 mol of 2-pyridineacetonitrile and 0.05 mol of 4,5-dichlorosalicylaldehyde (QL2a), 5-bromosalicylaldehyde (QL2b), or 5-chlorosalicylaldehyde (QL2C) were weighed out. Then, 40.0 mL of anhydrous ethanol (EtOH) and 1.5 mL of piperidine were added. The mixture was stirred at 37°C for 8.0 h and then reacted at 65°C for 8.0 h. The iminocoumarin derivatives were obtained by filtration and designated as QL2d, QL2e, and QL2f, respectively.
[0036] The iminocoumarin derivative was added to a 500 mL round-bottom flask, followed by the addition of HCl (35.0 mL, 15.0%) and H2O (5.0 mL). The mixture was reacted at 95°C for 9.0 h. The acidic solution was neutralized with concentrated ammonia water and filtered to obtain a light yellow solid.
[0037] Under heating conditions, the obtained yellow solid was dissolved and recrystallized with 10.0 mL of methanol. This process was repeated three times, followed by filtration. The final product was a pure light yellow product (yield of 78.2-89.5%), which is the coumarin derivative, denoted as H-QL3a, H-QL3b, and H-QL3c, respectively.
[0038] The synthetic route for coumarin derivatives is as follows:
[0039]
[0040] 1.2 Synthesis of the novel coumarin-ruthenium complex of the present invention
[0041] In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of coumarin derivative and an equal amount of cis-Ru(DMSO)4Cl2 were added, followed by 2.0 mL of CH3OH and 0.5 mL of CH2Cl2. After capping the drug-resistant tube, the mixture was reacted at 65 °C for 3 days, cooled to room temperature, and the system was opened and filtered to obtain the crude product. Then, using CH2Cl2 / MeOH (100:1-20:1, v / v) as the eluent, the product was purified by Al2O3 column chromatography to obtain a reddish-brown product (yield of 81.4–93.5%), which are the novel coumarin-ruthenium complexes of this invention, denoted as YNU-4i, YNU-4j, and YNU-4K, respectively.
[0042] The synthetic route for the novel coumarin ruthenium complex is as follows:
[0043]
[0044] 1.4 Identification of Products
[0045] 1.4.1 Perform nuclear magnetic resonance on the obtained product.
[0046] The NMR 1H and 1C spectra of coumarin derivatives and novel coumarin ruthenium complexes are shown below. Figure 1-7 .
[0047] Data for H-QL3a. Yield: 89.5%. 1 H NMR (400 MHz, DMSO-d6) δ 8.81 (s,1H), 8.72 (dd, J = 4.7, 0.7 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.03 (d, J =2.4 Hz, 1H), 7.97 (d, J = 1.7 Hz, 1H), 7.94 (t, J = 2.0 Hz, 1H), 7.49 (ddd, J= 7.5, 4.8, 0.8 Hz, 1H). 13 C NMR (101 MHz, DMSO-d6): δ 158.11, 149.84, 149.16,147.73, 141.01, 137.46, 131.43, 128.39, 127.53, 126.05, 124.33, 123.90,121.50, 120.55.
[0048] Data for H-QL3b. Yield: 78.2%. 1 H NMR (400 MHz, DMSO-d6): δ 8.82 (s,1H), 8.76 (ddd, J = 4.9, 1.6, 0.8 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.17 (d,J = 2.4 Hz, 1H), 8.06 (td, J = 7.8, 1.8 Hz, 1H), 7.82 (dd, J = 8.8, 2.4 Hz, 1H), 7.57 (ddd, J = 7.6, 5.0, 1.0 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H).
[0049] Data for H-QL3c. Yield: 80.9%. 1H NMR (400 MHz, DMSO-d6): δ 8.85 (s,1H), 8.76 (d, J = 4.3 Hz, 1H), 8.32 (d, J = 8.0 Hz, 1H), 8.07 (td, J = 7.9,1.6 Hz, 1H), 7.57 (dd, J = 7.2, 5.2 Hz, 1H), 7.46 (dd, J = 7.2, 1.9 Hz, 1H),7.37 (d, J = 4.1 Hz, 1H), 7.36 (q, J = 8.1 Hz, 1H)。
[0050] Data for YNU-4i. Yield: 93.5%. 1 H NMR (400 MHz, DMSO-d6): δ 8.85 (s,1H), 8.75 (d, J = 4.7 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 2.4 Hz,1H), 8.01 (d, J = 2.4 Hz, 1H), 7.98 (dd, J = 7.9, 1.7 Hz, 1H), 7.52 (ddd, J =7.5, 4.9, 0.9 Hz, 1H), 2.54 (s, 12H)。
[0051] Data for YNU-4j. Yield: 81.4%. 1 H NMR (400 MHz, DMSO-d6): δ 8.84 (s,1H), 8.75 (dd, J = 3.9, 0.8 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.21 (d, J =2.3 Hz, 1H), 8.01 (t, J = 7.8 Hz, 1H), 7.83 (dd, J = 8.8, 2.4 Hz, 1H), 7.53(dd, J = 7.5, 4.8 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 2.54 (s, 12H)。
[0052] Data for YNU-4k. Yield: 85.6%. 1H NMR (400 MHz, DMSO-d6): 8.84 (s,1H), 8.76 (dd, J = 4.9, 0.8 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.08 (d, J =2.5 Hz, 1H), 8.03 (td, J = 7.8, 1.8 Hz, 1H), 7.72 (dd, J = 8.9, 2.6 Hz, 1H), 7.54 (dd, J = 8.4, 1.0 Hz, 1H), 7.53 (d, J = 8.9 Hz, 1H), 2.54 (s, 12H).
[0053] 1.4.2 Elemental Analysis
[0054] The results are shown in Table 1.
[0055]
[0056] 1.4.3 Infrared Spectrum
[0057] Data for YNU-4i. Yield: 93.5%. IR (KBr):3936, 3451, 3227, 3147, 3118,3089, 3025, 3011, 2920, 2831, 2766, 1917, 1810, 1747, 1732, 1626, 1613, 1563,1532, 1457, 1446, 1390, 1366, 1308, 1288, 1278, 1245, 1174, 1118, 1090, 1019,999, 971, 959, 929, 917, 876, 832, 786, 759, 740, 718, 693, 679, 622, 611,581, 574, 539, 512, 424 cm −1 .
[0058] Data for YNU-4j. Yield: 81.4%. IR (KBr): 3442, 3086, 3047, 3012,2924, 1920, 1719, 1697, 1593, 1559, 1525, 1477, 1462, 1434, 1410, 1365, 1307,1290, 1240, 1220, 1178, 1141, 1097, 1021, 978, 944, 926, 889, 863, 847, 827,798, 765, 738, 718, 678, 658, 624, 586, 561, 524, 425 cm −1 .
[0059] Data for YNU-4k. Yield: 85.6%. IR (KBr): 3937, 3433, 3087, 3047,3013, 2925, 2822, 2694, 2049, 1732, 1720, 1705, 1612, 1594, 1565, 1525, 1479,1462, 1417, 1401, 1365, 1330, 1290, 1259, 1239, 1179, 1141, 1098, 1082, 1021,976, 933, 888, 869, 848, 799, 791, 765, 739, 718, 669, 678, 625, 584, 567,537, 525, 454, 425 cm −1 .
[0060] In summary, the structural formulas of the coumarin derivatives and the novel coumarin ruthenium complexes are determined as follows:
[0061] .
[0062] 2. In vitro and in vivo antitumor activity experiments of complex 1 and complex 2
[0063] 2.1 Cell lines and cell culture
[0064] Two human cell lines were selected: A549 / DDP, a drug-resistant human lung cancer cell line, and HEK293, a normal human embryonic kidney cell line.
[0065] All human cell lines were cultured in RPMI-1640 medium containing 100 U / mL penicillin, 10 wt% fetal blood, and 100 U / mL streptomycin, and incubated at 37°C in an incubator containing 5% CO2 by volume.
[0066] 2.2 Preparation of the test compound
[0067] All compounds had a purity ≥95%. Their DMSO stock solutions were diluted with physiological buffer to a final solution of 2.0 mmol / L (final DMSO concentration ≤1%). The inhibitory effect of each compound on the growth of normal cells and selected tumor cells was then tested.
[0068] 2.3 Cell growth inhibition assay (using CCK-8 assay)
[0069] The specific steps are as follows:
[0070] S1. Cells are digested, counted, and prepared to a concentration of 5 × 10⁻⁶. 4 Add 100 μL of cell suspension per well to a 96-well cell culture plate and incubate at 37°C in a 5% CO2 incubator for 24 h.
[0071] S2. Dilute the drug to the required concentration using RPMI-1640 medium. Add 100 μL of the corresponding drug-containing medium to each well of a 96-well plate to achieve final concentrations of 0, 1.0, 2.5, 5.0, 10.0, and 20.0 μM, respectively. Set up 6 parallel experiments for each concentration. After adding the drug, incubate at 37℃ in a 5% CO2 incubator for 48 h. Use the 0 concentration as a control.
[0072] S3. Perform CCK-8 staining and measure OD values at a wavelength of λ=450nm: Add 10μL of CCK-8 to each well, continue incubation for 2 hours, gently mix by shaking for 10 minutes, and then measure the OD value of each well at a wavelength of λ=450nm using a microplate reader. Calculate the inhibition rate of each compound on the growth of the selected cell lines, and then calculate the IC50 of each tested compound on the selected cell lines using the Bliss method. 50 Values. The results are shown in Table 2 below.
[0073]
[0074] As shown in Table 2, from IC 50 The results showed that the novel coumarin-ruthenium complexes YNU-4i, YNU-4j, and YNU-4k of this invention had a good inhibitory effect on the cisplatin-resistant human lung cancer cell line A549 / DDP, with an IC50 concentration of 100 mg / kg / dt. 50 The values were 9.31±0.60µM, 14.38±0.44µM and 11.02±1.02µM, respectively, which were much smaller than those of H-QL3a, H-QL3b, H-QL3c, the metal salt cis-Ru(DMSO)4Cl2 and the clinical drug cisplatin.
[0075] In addition, the novel coumarin ruthenium complexes YNU-4i, YNU-4j and YNU-4k of this invention also have very low toxicity to normal HEK293 cell lines, indicating that the novel coumarin ruthenium complexes of this invention are selective for human lung cancer cisplatin-resistant cell line A549 / DDP.
[0076] In summary, the novel coumarin-ruthenium complex of this invention exhibits superior antitumor activity and can overcome cisplatin resistance, demonstrating potential pharmaceutical value and promising applications in the preparation of various antitumor drugs.
[0077] The foregoing description of specific exemplary embodiments of the invention is for illustrative and explanatory purposes. These descriptions are not intended to limit the invention to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the foregoing teachings. The exemplary embodiments were chosen and described in order to explain the specific principles of the invention and its practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the invention, as well as various different choices and variations. The scope of the invention is intended to be defined by the claims and their equivalents.
Claims
1. A novel coumarin ruthenium complex, characterized in that, The structural formula of the novel coumarin ruthenium complex is as follows: , Where R3 is H or Cl; R4 is Cl or Br.
2. The novel coumarin ruthenium complex according to claim 1, characterized in that, The method for synthesizing the novel coumarin ruthenium complex is as follows: Weigh 0.2 mmol of coumarin derivative and 0.2 mmol of metal salt cis-Ru(DMSO)4Cl2, then add 2.0 mL of CH3OH and 0.5 mL of CH2Cl2. React at 50-90 °C for 3 days, then cool to room temperature, filter to obtain crude product, and then purify by Al2O3 column chromatography with CH2Cl2 / MeOH at a volume ratio of 100:1-20:1 to obtain reddish-brown product, which is the novel coumarin ruthenium complex.
3. The novel coumarin ruthenium complex according to claim 2, characterized in that, The structural formula of the coumarin derivative is as follows: Where R3 is H or Cl; R4 is Cl or Br.
4. The novel coumarin ruthenium complex according to claim 1, characterized in that, The method for synthesizing the coumarin derivative is as follows: Weigh 0.05 mol of 2-pyridineacetonitrile and 0.05 mol of 4,5-dichlorosalicylic acid, 5-bromosalicylic acid, or 5-chlorosalicylic acid, then add 40.0 mL of anhydrous ethanol and 1.5 mL of piperidine. Stir the mixture at 37°C for 8.0 h, then react at 65°C for 8.0 h. Filter the mixture to obtain an iminocoumarin derivative. Add 35.0 mL of 15% HCl and 5.0 mL of H2O to the iminocoumarin derivative and react at 95°C for 9.0 h. Neutralize with concentrated ammonia water until neutral, filter the mixture to obtain a light yellow solid. Dissolve and recrystallize the obtained yellow solid with 10.0 mL of methanol under heating conditions. Repeat this process three times, filter the mixture, and finally obtain a pure light yellow product, which is the coumarin derivative.
5. The use of the novel coumarin ruthenium complex of claim 1 in the preparation of antitumor drugs.
6. The application according to claim 5, characterized in that, The tumor is human lung cancer.
7. An in vitro and in vivo antitumor drug, characterized in that, The in vitro and in vivo antitumor drug uses the novel coumarin-ruthenium complex as described in claim 1 as its active ingredient.
